New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
17:23 EDTDEPO, SNTSSantarus announces receipt of paragraph IV certification for generic glumetza
Santarus (SNTS) disclosed that on January 21, Santarus received a paragraph IV certification from Watson Laboratories advising Santarus of the filing of an Abbreviated New Drug Application ANDA with the U.S. FDA for a generic version of Glumetza. Santarus promotes Glumetza in the U.S. under the terms of a commercialization agreement with Depomed (DEPO). Watson’s certification notice alleges that the four U.S. patents listed in the FDA’s Orange Book for Glumetza 500 mg, with expiration dates in 2016, 2020 and 2021, will not be infringed by Watson’s proposed product, are invalid and/or are unenforceable. Santarus and Depomed are evaluating the paragraph IV certification. The parties have 45 days from the receipt of the paragraph IV certification to commence a patent infringement lawsuit against Watson that would automatically stay, or bar, the FDA from approving Watson’s ANDA for 30 months or until a district court decision that is adverse to the asserted patents, whichever is earlier. In April 2012, Depomed filed a lawsuit against Watson in the U.S. District Court for the District of Delaware, in response to an ANDA and paragraph IV certification filed by Watson regarding Watson’s intent to market a generic version of Glumetza 1000 mg, which litigation is ongoing.
News For SNTS;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:01 EDTDEPOOn The Fly: Analyst Initiation Summary
Today's noteworthy imitations include: ANSYS (ANSS) initiated with an Overweight at Mitsubishi UFJ... Antero Midstream (AM) initiated with a Buy at Janney Capital... Autodesk (ADSK) initiated with a Neutral at Mitsubishi UFJ... Cheesecake Factory (CAKE) initiated with a Buy at Maxim... Depomed (DEPO) initiated with a Buy at UBS... Fleetmatics (FLTX) initiated with a Market Perform at Avondale... Glaukos (GKOS) initiated with an Overweight at Piper Jaffray... La Jolla (LJPC) initiated with an Outperform at Cowen... Manhattan Associates (MANH) initiated with a Market Perform at Avondale... Metabolix (MBLX) initiated with a Buy at Rodman & Renshaw... Opower (OPWR) initiated with an Outperform at Avondale... Social Reality (SCRI) initiated with a Buy at Rodman & Renshaw... Splunk (SPLK) initiated with an Overweight at Mitsubishi UFJ... Sucampo (SCMP) initiated with a Buy at UBS... Ultragenyx (RARE) initiated with a Buy at H.C. Wainwright... Workday (WDAY) initiated with an Overweight at Mitsubishi UFJ.
05:40 EDTDEPODepomed initiated with a Buy at UBS
Subscribe for More Information
February 8, 2016
10:22 EDTDEPOOak Ridge reports 5.04% passive stake in Depomed
10:00 EDTDEPOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:03 EDTDEPODepomed announces favorable Markman ruling in Nucynta, Nucynta ER litigation
Subscribe for More Information
06:34 EDTDEPODepomed initiated with an Overweight at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use